Core Insights - Tvardi Therapeutics, Inc. experienced a significant decline in its stock price, dropping over 80% following disappointing preliminary data from its Phase 2 REVERT clinical trial for TTI-101 in idiopathic pulmonary fibrosis [3]. Company Overview - Tvardi Therapeutics, Inc. is currently under investigation by Faruqi & Faruqi, LLP for potential claims related to the significant losses suffered by investors [2]. Clinical Trial Results - The Phase 2 REVERT clinical trial aimed to evaluate safety, pharmacokinetics, and exploratory outcomes related to lung function, but the preliminary data indicated that the study did not meet its goals [3]. - The preliminary data showed that patients' baseline characteristics were similar across treatment arms, except for the percent predicted Forced Vital Capacity (FVC), which was lower in the placebo group compared to the TTI-101 treatment group [3].
TVRD INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Tvardi Therapeutics
Businesswire·2025-10-13 22:27